Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
27.41
+0.09 (0.33%)
At close: Mar 19, 2026, 4:00 PM EDT
27.37
-0.04 (-0.15%)
Pre-market: Mar 20, 2026, 6:48 AM EDT
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 | Mar '20 Mar 29, 2020 |
Primary Care Revenue | 7.94B | |||||||||||||||||||||||
Primary Care Revenue Growth | -10.92% | |||||||||||||||||||||||
Specialty Care Revenue | 4.77B | |||||||||||||||||||||||
Specialty Care Revenue Growth | 7.50% | |||||||||||||||||||||||
Oncology Revenue | 4.44B | |||||||||||||||||||||||
Oncology Revenue Growth | 9.13% | |||||||||||||||||||||||
Global Pharmaceuticals Business (Biopharma) Revenue | 17.14B | |||||||||||||||||||||||
Global Pharmaceuticals Business (Biopharma) Revenue Growth | -1.54% | |||||||||||||||||||||||
Business Innovation (Pfizer CentreOne) Revenue | 409.00M | |||||||||||||||||||||||
Business Innovation (Pfizer CentreOne) Revenue Growth | 25.85% | |||||||||||||||||||||||
Revenue (Other) | 4.00M | |||||||||||||||||||||||
Revenue (Total) | 17.56B | |||||||||||||||||||||||
Revenue (Total) Growth | -1.16% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 | Mar '20 Mar 29, 2020 |
United States Revenue | 9.12B | |||||||||||||||||||||||
United States Revenue Growth | -1.11% | |||||||||||||||||||||||
Developed Markets Revenue | 5.92B | |||||||||||||||||||||||
Developed Markets Revenue Growth | -5.76% | |||||||||||||||||||||||
Emerging Markets Revenue (Post-FY2023 Reporting) | 2.52B | |||||||||||||||||||||||
Emerging Markets Revenue (Post-FY2023 Reporting) Growth | 11.42% | |||||||||||||||||||||||
Revenue (Total) | 17.56B | |||||||||||||||||||||||
Revenue (Total) Growth | -1.16% |
Revenue by Geography 2
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 | Mar '20 Mar 29, 2020 |
United States Revenue | 9.12B | |||||||||||||||||||||||
United States Revenue Growth | -1.11% | |||||||||||||||||||||||
Revenue (Total) | 17.56B | |||||||||||||||||||||||
Revenue (Total) Growth | -1.16% |
Revenue by Geography 3
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 | Mar '20 Mar 29, 2020 |
United States Revenue | 9.12B | |||||||||||||||||||||||
United States Revenue Growth | -1.11% | |||||||||||||||||||||||
International Revenue | 8.44B | |||||||||||||||||||||||
International Revenue Growth | -1.22% | |||||||||||||||||||||||
Revenue (Total) | 17.56B | |||||||||||||||||||||||
Revenue (Total) Growth | -1.16% |
EBT
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 | Mar '20 Mar 29, 2020 |
Global Pharmaceuticals Business (Biopharma) Earnings | 6.84B | |||||||||||||||||||||||
Global Pharmaceuticals Business (Biopharma) Earnings Growth | 10.65% | |||||||||||||||||||||||
Other Business Activities Earnings | -1.90B |
Key Performance Indicators
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 28, 2025 | Jun '25 Jun 29, 2025 | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 29, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Oct '23 Oct 1, 2023 | Jul '23 Jul 2, 2023 | Apr '23 Apr 2, 2023 | Dec '22 Dec 31, 2022 | Oct '22 Oct 2, 2022 | Jul '22 Jul 3, 2022 | Apr '22 Apr 3, 2022 | Dec '21 Dec 31, 2021 | Oct '21 Oct 3, 2021 | Jul '21 Jul 4, 2021 | Apr '21 Apr 4, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 27, 2020 | Jun '20 Jun 28, 2020 | Mar '20 Mar 29, 2020 |
Comirnaty Direct Sales and Alliance Revenue | 2.27B | |||||||||||||||||||||||
Comirnaty Direct Sales and Alliance Revenue Growth | -32.87% | |||||||||||||||||||||||
Eliquis Alliance Revenue and Direct Sales | 2.02B | |||||||||||||||||||||||
Eliquis Alliance Revenue and Direct Sales Growth | 10.26% | |||||||||||||||||||||||
Paxlovid Revenue | 218.00M | |||||||||||||||||||||||
Paxlovid Revenue Growth | -70.01% | |||||||||||||||||||||||
Prevnar Family Revenue | 1.71B | |||||||||||||||||||||||
Prevnar Family Revenue Growth | 9.63% | |||||||||||||||||||||||
Nurtec ODT/Vydura Revenue | 405.00M | |||||||||||||||||||||||
Nurtec ODT/Vydura Revenue Growth | 3.32% | |||||||||||||||||||||||
Abrysvo Revenue | 481.00M | |||||||||||||||||||||||
Abrysvo Revenue Growth | 142.93% | |||||||||||||||||||||||
Vyndaqel Family Revenue | 1.69B | |||||||||||||||||||||||
Vyndaqel Family Revenue Growth | 9.26% | |||||||||||||||||||||||
Xeljanz Revenue | 324.00M | |||||||||||||||||||||||
Xeljanz Revenue Growth | -7.16% | |||||||||||||||||||||||
Ibrance Revenue | 1.04B | |||||||||||||||||||||||
Ibrance Revenue Growth | -5.02% |
Updated Feb 3, 2026. Data Source: Fiscal.ai.